Introduction: The rates of alcohol and illegal drug use and the prevalence of alcohol and illegal drug use disorders (AUDs and DUDs) are high in prison populations, particularly in men entering jail. However, these rates have never been exhaustively assessed and compared to those of the general population in France. Methods: We based our research on two surveys, conducted in the same French region, which included a total of 630 men entering jail and 5,793 men recruited from the general population. We used the Mini-International Neuropsychiatric Interview to assess alcohol and drug use, AUD, DUD, as well as co-occurring psychiatric disorders, and we examined differences in prevalence rates between the two populations. Logistic regression models were performed to (i) identify the factors associated with AUD and DUD and (ii) test whether the interaction between admission to jail and the presence of AUD, DUD, or both is linked to the presence of at least one co-occurring psychiatric disorder. Results: Compared to the general population sample, the prevalence of AUD (33.8% vs. 8.7%, p < 0.001) and DUD (at least one type of drug: 28.7% vs. 5.0%, p < 0.001; cannabis: 24.0% vs. 4.7%, p < 0.001; opioids: 6.8% vs. 0.4%, p < 0.001; stimulants: 5.2% vs. 0.8%, p < 0.001) was significantly higher in the jail population sample, as well as the rates of past-year use of various substances (alcohol: 62.1% vs. 56.4%, p = 0.007; at least one type of illegal drug: 50.0% vs. 14.4%, p < 0.001; cannabis: 45.6% vs. 13.9%, opioids: 9.4% vs. 0.7%; stimulants: 8.6% vs. 1.9%). Admission to jail was associated with a higher risk of AUD (aOR = 3.80, 95% CI: 2.89–5.01, p < 0.001) or DUD (aOR = 4.25, 95% CI: 3.10–5.84, p < 0.001). History of trauma was also associated with both AUD (aOR = 1.81, 95% CI: 1.53–2.14, p < 0.001) and DUD (aOR = 2.15, 95% CI: 1.74–2.65, p < 0.001), whereas history of migration was only associated with DUD (aOR = 1.38, 95% CI: 1.12–1.71, p = 0.003). AUDs and DUDs were more strongly associated with co-occurring psychiatric disorders in incarcerated men than in the general population. Among individuals with AUD, DUD, or both, co-occurring anxiety and mood disorders were particularly more frequent in jail than in the general population. Discussion/Conclusion: As in most countries, AUD and DUD are highly prevalent among men entering jail in France. Our results also suggest that incarceration constitutes an independent vulnerability factor for a dual disorder, which supports a systematic assessment and treatment of psychiatric disorders in men entering jail and diagnosed with an AUD or DUD.

1.
Penal Reform International
.
Global prison trends 2020 [Internet]
.
Penal Reform International
;
2020
[cited 2020 Apr 28]. Available from: https://www.penalreform.org/resource/global-prison-trends-2020/.
2.
Fazel
S
,
Hayes
AJ
,
Bartellas
K
,
Clerici
M
,
Trestman
R
.
Mental health of prisoners: prevalence, adverse outcomes, and interventions
.
Lancet Psychiatry
.
2016 Sep
;
3
(
9
):
871
81
. .
3.
Fazel
S
,
Yoon
IA
,
Hayes
AJ
.
Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women
.
Addict Abingdon Engl
.
2017 Oct
;
112
(
10
):
1725
39
. .
4.
Rivlin
A
,
Hawton
K
,
Marzano
L
,
Fazel
S
.
Psychiatric disorders in male prisoners who made near-lethal suicide attempts: case-control study
.
Br J Psychiatry
.
2010 Oct
;
197
(
4
):
313
9
. .
5.
Radeloff
D
,
Ten Hövel
M
,
Brennecke
G
,
Stoeber
FS
,
Lempp
T
,
Kettner
M
,
Suicide after reception into prison: a case-control study examining differences in early and late events
.
PLoS One
.
2021 Aug
;
16
(
8
):
e0255284
. .
6.
Kinner
SA
,
Forsyth
S
,
Williams
G
.
Systematic review of record linkage studies of mortality in ex-prisoners: why (good) methods matter
.
Addict Abingdon Engl
.
2013 Jan
;
108
(
1
):
38
49
. .
7.
Chang
Z
,
Lichtenstein
P
,
Larsson
H
,
Fazel
S
.
Substance use disorders, psychiatric disorders, and mortality after release from prison: a nationwide longitudinal cohort study
.
Lancet Psychiatry
.
2015 May
;
2
(
5
):
422
30
. .
8.
Chang
Z
,
Larsson
H
,
Lichtenstein
P
,
Fazel
S
.
Psychiatric disorders and violent reoffending: a national cohort study of convicted prisoners in Sweden
.
Lancet Psychiatry
.
2015 Oct
;
2
(
10
):
891
900
. .
9.
Steiner
B
,
Wooldredge
J
.
Inmate versus environmental effects on prison rule violations
.
Crim Justice Behav
.
2008 Apr
;
35
(
4
):
438
56
. .
10.
Oser
CB
,
Knudsen
HK
,
Staton-Tindall
M
,
Taxman
F
,
Leukefeld
C
.
Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions
.
Drug Alcohol Depend
.
2009 Aug
;
103
(
Suppl 1
):
S73
81
. .
11.
Wakeman
SE
,
Rich
JD
.
Pharmacotherapy for substance use disorders within correctional facilities
.
Oxford University Press
;
2015
.
12.
Mundt
AP
,
Baranyi
G
,
Fazel
S
.
Incomplete discussion of bipolar disorder and comorbid substance use disorder: authors’ reply
.
Lancet Glob Health
.
2019
;
7
(
7
):
e847
. .
13.
Mir
J
,
Kastner
S
,
Priebe
S
,
Konrad
N
,
Ströhle
A
,
Mundt
AP
.
Treating substance abuse is not enough: comorbidities in consecutively admitted female prisoners
.
Addict Behav
.
2015 Jul
;
46
:
25
30
. .
14.
Abram
KM
,
Zwecker
NA
,
Welty
LJ
,
Hershfield
JA
,
Dulcan
MK
,
Teplin
LA
.
Comorbidity and continuity of psychiatric disorders in youth after detention: a prospective longitudinal study
.
JAMA Psychiatry
.
2015 Jan
;
72
(
1
):
84
93
. .
15.
Ignatyev
Y
,
Baggio
S
,
Mundt
AP
.
The underlying structure of comorbid mental health and substance use disorders in prison populations
.
Psychopathology
.
2019
;
52
(
1
):
2
9
. .
16.
Fovet
T
,
Plancke
L
,
Amariei
A
,
Benradia
I
,
Carton
F
,
Sy
A
,
Mental disorders on admission to jail: a study of prevalence and a comparison with a community sample in the north of France
.
Eur Psychiatry
.
2020 Apr
;
63
(
1
):
e43
. .
17.
Bartlett
A
,
Hollins
S
.
Challenges and mental health needs of women in prison
.
Br J Psychiatry
.
2018
;
212
(
3
):
134
6
. .
18.
Bellamy
V
,
Roelandt
JL
,
Caria
A
.
Premiers résultats de l’enquête Santé mentale en population générale: images et réalités
.
Inf Psychiatr
.
2005 Apr
;
81
(
4
):
295
304
.
19.
Caria
A
,
Roelandt
J-L
,
Bellamy
V
,
Vandeborre
A
.
[“Mental health in the general population: images and realities (MHGP)”: methodology of the study]
.
Encephale
.
2010
;
36
(
3 Suppl l
):
1
6
. .
20.
Amad
A
,
Guardia
D
,
Salleron
J
,
Thomas
P
,
Roelandt
J-L
,
Vaiva
G
.
Increased prevalence of psychotic disorders among third-generation migrants: results from the French Mental Health in General Population survey
.
Schizophr Res
.
2013 Jun
;
147
(
1
):
193
5
. .
21.
Pignon
B
,
Geoffroy
PA
,
Thomas
P
,
Roelandt
J-L
,
Rolland
B
,
Morgan
C
,
Prevalence and clinical severity of mood disorders among first-second- and third-generation migrants
.
J Affect Disord
.
2017 Mar
;
210
:
174
80
. .
22.
Pignon
B
,
Amad
A
,
Pelissolo
A
,
Fovet
T
,
Thomas
P
,
Vaiva
G
,
Increased prevalence of anxiety disorders in third-generation migrants in comparison to natives and to first-generation migrants
.
J Psychiatr Res
.
2018 Jul
;
102
:
38
43
. .
23.
Sheehan
DV
,
Lecrubier
Y
,
Sheehan
KH
,
Amorim
P
,
Janavs
J
,
Weiller
E
,
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
.
J Clin Psychiatr
.
1998
;
59
(
Suppl 20
):
22
33
; quiz 34–57.
24.
Lecrubier
Y
,
Sheehan
DV
,
Weiller
E
,
Amorim
P
,
Bonora
I
,
Sheehan
KH
,
The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
.
Eur Psychiatr
.
1997
;
12
(
5
):
224
31
. .
25.
Sheehan
D
,
Lecrubier
Y
,
Harnett Sheehan
K
,
Janavs
J
,
Weiller
E
,
Keskiner
A
,
The validity of the Mini international neuropsychiatric interview (MINI) according to the SCID-P and its reliability
.
Eur Psychiatry
.
1997 Jan
;
12
(
5
):
232
41
. .
26.
Porta
M
.
A dictionary of epidemiology
.
Oxford University Press
;
2016
.
27.
Johnston
R
,
Jones
K
,
Manley
D
.
Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour
.
Qual Quant
.
2018
;
52
(
4
):
1957
76
. .
28.
Rousselet
M
,
Guerlais
M
,
Caillet
P
,
Le Geay
B
,
Mauillon
D
,
Serre
P
,
Consumption of psychoactive substances in prison: between initiation and improvement, what trajectories occur after incarceration? COSMOS study data
.
PLoS One
.
2019 Dec
;
14
(
12
):
e0225189
. .
29.
Sarlon
E
,
Duburcq
A
,
Neveu
X
,
Morvan-Duru
E
,
Tremblay
R
,
Rouillon
F
,
Imprisonment, alcohol dependence and risk of delusional disorder: a cross-sectional study
.
Rev Epidemiol Sante Publique
.
2012 Jun
;
60
(
3
):
197
203
. .
30.
Falissard
B
,
Loze
J-Y
,
Gasquet
I
,
Duburc
A
,
de Beaurepaire
C
,
Fagnani
F
,
Prevalence of mental disorders in French prisons for men
.
BMC Psychiatr
.
2006 Aug
;
6
:
33
. .
31.
Castillo-Carniglia
A
,
Keyes
KM
,
Hasin
DS
,
Cerdá
M
.
Psychiatric comorbidities in alcohol use disorder
.
Lancet Psychiatr
.
2019 Dec
;
6
(
12
):
1068
80
. .
32.
European Monitoring Centre for Drugs and Drug Addiction
.
Comorbidity of substance use and mental health disorders in Europe (Perspectives on drugs) [Internet]
;
2016
[cited 2022 Jun 13]. Available from: https://www.emcdda.europa.eu/publications/pods/comorbidity-substance-use-mental-health_en.
33.
Szerman
N
,
Peris
L
.
Precision psychiatry and dual disorders
.
J Dual Diagn
.
2018 Oct–Dec
;
14
(
4
):
237
46
. .
34.
Butler
A
,
Nicholls
T
,
Samji
H
,
Fabian
S
,
Lavergne
MR
.
Prevalence of mental health needs, substance use, and co-occurring disorders among people admitted to prison
.
Psychiatr Serv
.
2022
;
73
(
7
):
737
44
. .
35.
Reingle Gonzalez
JM
,
Connell
NM
.
Mental health of prisoners: identifying barriers to mental health treatment and medication continuity
.
Am J Public Health
.
2014 Dec
;
104
(
12
):
2328
33
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.